New class of HIV treatment could end the road for Indian players. We raise red flag over Indian drug suppliers who are exposed to Global Fund and sovereign Institutional tender business as the spread of Covid-19 could divert global attention away from serious diseases (Malaria, TB, and AIDS) and the new class of HIV treatment could end the road for Indian ARV (Antiretroviral) suppliers. The immediate threat to Indian suppliers because of Corona virus (SARS-nCOV2) will be felt in near to medium term as 1) COVID has disrupted 85% Global Funds activities for HIV, TB and malaria...